|
Jan 10
|
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01
|
|
Dec 7
|
First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIa Study within the Tumorad(R) Program
|
|
Oct 19
|
Spago Nanomedical Receives Approval to Initiate the Clinical Phase I/IIa study with Tumorad(R) in Australia
|